EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months



Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months



Toxicological Sciences 69(1): 244-257



Ammonium perfluorooctanoate (APFO) is a processing aid in the production of fluoropolymers that has been shown to have a long half-life in human blood. To understand the potential toxicological response of primates, groups of male cynomolgus monkeys were given daily po (capsule) doses of either 0, 3, 10, or 30 (reduced to 20) mg/kg/day for 26 weeks. Two monkeys from each of the control and 10 mg/kg/day dose groups were observed for 90 days after the last dose. Clinical observations, clinical chemistry, determination of key hormones, gross and microscopic pathology, cell proliferation, peroxisomal proliferation, bile-acid determination, and serum and liver perfluorooctanoate (PFOA) concentrations were monitored. Toxicity, including weight loss and reduced food consumption, was noted early in the study at the 30 mg/kg/day dose; therefore, the dose was reduced to 20 mg/kg/day. The same signs of toxicity developed in 3 monkeys at 20 mg/kg/day, after which treatment of these monkeys was discontinued. One 30/20 mg/kg/day monkey developed the signs of toxicity noted above and a possible dosing injury, and this monkey was sacrificed in extremis on Day 29. A 3 mg/kg/day dose-group monkey was sacrificed in extremis on Day 137 for reasons not clearly related to APFO treatment. Dose-dependent increases in liver weight as a result of mitochondrial proliferation occurred in all APFO-treated groups. Histopathologic evidence of liver injury was not observed at either 3 or 10 mg/kg/day. Evidence of liver damage was seen in the monkey sacrificed in moribund condition at the highest dose. Body weights were decreased at 30/20 mg/kg. PFOA concentrations in serum and liver were highly variable, were not linearly proportional to dose, and cleared to background levels within 90 days after the last dose. A no observable effect level was not established in this study, and the low dose of 3 mg/kg/day was considered the lowest observable effect level based on increased liver weight and uncertainty as to the etiology leading to the moribund sacrifice of one low-dose monkey on Day 137. Other than those noted above, there were no APFO-related macroscopic or microscopic changes, changes in clinical chemistry, hormones, or urinalysis, or hematological effects. In particular, effects that have been associated with the development of pancreatic and testicular toxicity in rats were not observed in this study.

(PDF emailed within 0-6 h: $19.90)

Accession: 011578505

Download citation: RISBibTeXText

PMID: 12215680

DOI: 10.1093/toxsci/69.1.244



Related references

Longitudinal studies of cardiac troponin I concentrations in serum from male cynomolgus monkeys: resting values and effects of oral and intravenous dosing on biologic variability. Veterinary Clinical Pathology 44(3): 465-471, 2015

Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys. Journal of Toxicological Sciences 32(4): 411-420, 2007

13-week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug and Chemical Toxicology 27(4): 361-378, 2004

Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO). Toxicology 225(2-3): 195-203, 2006

Disposition in cynomolgus monkeys of the oral delivery agent P414 following IV and PO dosing. Pharmaceutical Research (New York) 13(9 SUPPL ): S508, 1996

Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. Toxicological Sciences 82(2): 394-406, 2004

30-day oral toxicity study of domoic acid in cynomolgus monkeys: lack of overt toxicity at doses approaching the acute toxic dose. Natural Toxins 5(3): 111-114, 1997

The effect of guanidine: (1). On experimental poliomyelitis induced by oral administration of virus to cynomolgus monkeys; (2). On naturally occurring enteroviruses of cynomolgus monkeys. Texas Reports on Biology and Medicine 19: 529-539, 1961

Four-week oral toxicity study on NK433 in cynomolgus monkeys. Preclinical Reports of the Central Institute for Experimental Animals 20(1): 37-54, 1995

Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys. Food & Chemical Toxicology 35(5): 465-474, 1997

Oral acute toxicity study on NK433 in cynomolgus monkeys. Preclinical Reports of the Central Institute for Experimental Animals 19(3): 165-171, 1993-, 1994

Evaluation of timefurone, a new anti-atherosclerotic drug, for its effects on lipoprotein cholesterol in male cynomolgus monkeys fed an atherogenic diet for 18 months. Atherosclerosis 56(3): 301-311, 1985

One year oral toxicity study of levonorgestrel in female cynomolgus monkeys. Oyo Yakuri 42(3): 301-312, 1991

Acute toxicity of oral diquat (1,1'-ethylene-2,2'-bipyridinium) in cynomolgus monkeys. Toxicology and Applied Pharmacology 51(2): 277-282, 1979